





Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-03)

Use for form 1449/PTO.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

### Complete if Known

Application Number	09/690,044
Filing Date	October 16, 2000
First Named Inventor	Per Lennart Lindberg
Art Unit	1625
Examiner Name	Fan, Jane T.
Attorney Docket Number	1103326-0072

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
a	D1-Binder. 1.	EP-0 005 129 A.1	10-31-1979			
	D2-Binder. 1.	EP-0 124 495 A2	11-07-1984			
	D3-Binder. 1.	DE-40 35 455 A.1	05-14-1997			
	D10-Binder. 1.	EP-01.662 87 B.1	01-02-1986			
	D12-Binder. 1.	WO 88/03921(Page 35)	06-02-1988			
u	D1-Binder. 2	EP-0 652 872	05-17-1995			

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
a	D4-Binder. 1.	J. MARCH, Advanced Organic Chemistry, 4 <sup>th</sup> edition (1992), John Wiley & Sons, pages 100, 120, 121, 378 and 379.	
	D5-Binder. 1	A. PILBRANT and C. CEDERBERG, "Development of an oral formulation of omeprazole", Scandinavian Journal of Gastroenterology, Volume 20, Supplement 108 (1985), pages 113-120.	
	D6-Binder. 1.	Beyer-Walter, Lehrbuch der Organischen Chemie [Textbook of organic chemistry], 22 <sup>nd</sup> edition (1991), S. Hirzel Verlag, Stuttgart, pages 735-736.	
	D7-Binder. 1.	H.J. FEDERSEL, "Chiral Arzneimittel", Chemie in unserer Zeit (1993)/No. 2, VCH Verlagsgesellschaft mbH, pages 78-87.	
	D8-Binder. 1	D. ENDERS and R.W. HOFFMANN, "Asymmetrische Synthese", Chemie in unserer Zeit (1985)/No. 6, VCH Verlagsgesellschaft mbH, pages 177-190.	
	D9-Binder. 1.	Clinical studies A and B by Astra Hässle AB, introduced into the grant proceedings.	
	D11-Binder. 1.	Methoden der Organischen Chemie (Houben Weyl) [Methods of organic chemistry, Houben Weyl], volume I/1, 1958, chapter "Crystallization", pages 345-389.	
	D13-Binder. 1.	P. LINDBERG <i>et al.</i> , "Omeprazole: The First Proton Pump Inhibitor", Medicinal Research Reviews, Vol. 10, No. 1, 1-54 (1990).	
	D14-Binder. 1.	P. ERLANDSSON <i>et al.</i> , "Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoylcellulose-based stationary phase: The effect of the enantiomers of omeprazole on gastric glands", Journal of Chromatography 532 (1990) 305-319.	
	D15-Binder. 1.	W. FORTH <i>et al.</i> , "Allgemeine und spezielle Pharmakologie und Toxikologie" [General and special pharmacology and toxicology], Wissenschaftsverlag, 6 <sup>th</sup> edition 1992, pages 33, 34, 55-57, 70, 472 and 473.	
u	D16-Binder. 1.	M. EICHELBAUM <i>et al.</i> , "Effects of Verapamil on P-R-Intervals in Relation to Verapamil Plasma Levels Following Single i.v. and Oral Administration and During Chronic Treatment, Klinische Wochenschrift 58, 919-925 (1980).	
Examiner Signature		<i>clw</i>	Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST-3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. \*Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	09/690,044
Filing Date	October 16, 2000
First Named Inventor	Per Lennart Lindberg
Art Unit	1625
Examiner Name	Fan, Jane T.
Attorney Docket Number	1103326-0072

Sheet 2 of 3

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
u	D17-Binder 1	P. DAYER <i>et al.</i> , "Interindividual Variation of Beta-Adrenoceptor Blocking Drugs, Plasma Concentration and Effect: Influence of Genetic Status on Behavior of Atenolol, Bopindolol and Metoprolol, Eur. J. Clin. Pharmacol. (1985) 28(2): 149-153.	
	D18-Binder 1	"The result of a recent study comparing all PPI's currently on the market".	
	D19-Binder 1	P. FRESENIUS, "Organic Chemical Nomenclature, Introduction to the Basic Principles", Ellis Horwood Limited, page 127.	
	D20-Binder 1	S. YAMADA and S. NARITA, "Synthesis and Isomerization of Optical Active 2[(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)sulfinyl]-1H-benzimidazole Analogs" Chem. Pharm. Bull 42(8), 1679-1681 (1994).	
	D21-Binder 1	JACOBUS <i>et al.</i> , "Racemization and Cleavage of Sulfoxides by Methylolithium", Journal of the American Chemical Society 89:20; pages 5228-5234 (1967).	
	D22-Binder 1	TANAKA, M. <i>et al.</i> , "Direct Determination of Pantoprazole Enantiomers in Human Serum by Reversed-Phase High-Performance Liquid Chromatography Using a Cellulose-Based Chiral Stationary Phase and Column-Switching System as a Sample Cleanup Procedure", Analytical Chemistry, Vol. 68, No. 9, 1513-1516 (1996)	
	D23-Binder 1	CASS <i>et al.</i> , "Enantiomeric determination of pantoprazole in human plasma by multidimensional high-performance liquid chromatography", J. Chromatography B, 766 (2001) 153-160.	
	D24-Binder 1	Comprehensive Medicinal Chemistry, Pergamon Press (1990), Volume 2, pages 193- 205.	
	D25-Binder 1	RENBURG <i>et al.</i> , "Identification of Two Main Urinary Metabolites of [ <sup>14</sup> C]Omeprazole in Humans", Drug Metabolism and Disposition, Vol 17, (1989) 69-76.	
	D26-Binder 1	Abstract #35, "Synthesis and Biological Activity of Enantiomers of H <sup>+</sup> K <sup>+</sup> -ATPase Inhibiting 2-(2-Pyridyl-methyl) sulphinyl-benzimidazoles (PSBs) from Program of the Fourth International Symposium of Chiral Discrimination, 19-22 September 1993, Montreal, Quebec, Canada.	
	D2-Binder 2	In the matter of EP 0 652 872, Notice of Opposition and Opposition Brief in the name of Ratiopharm GmbH, dated 18 July 2001.	X
	D3-Binder 2	In the matter of EP 0 652 872, Response to the Opposition Brief by AstraZeneca AB, dated 27 March 2002.	
	D4-Binder 2	In the matter of EP 0 652 872, third party observations, dated 30 May 2002.	
	D5-Binder 2	In the matter of EP 0 652 872, opponent submission, dated 22 January 2003.	X
u	D6-Binder 2	In the matter of EP 0 652 872, summons to oral proceedings, dated 15 July, 2003.	
Examiner Signature		<i>Ch</i>	Date Considered
			7/21/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

